AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "outperform" rating reiterated by equities research analysts at Wedbush in a report released on Wednesday, RTT News reports. They presently have a $42.00 target price on the biotechnology company's stock. Wedbush's price target would suggest a potential upside of 85.59% from the company's current price.
ANAB has been the subject of several other reports. Guggenheim boosted their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Monday, October 21st. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of AnaptysBio in a report on Thursday, October 31st. Truist Financial upped their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Finally, UBS Group lifted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $55.73.
Check Out Our Latest Research Report on ANAB
NASDAQ:ANAB traded up $2.75 during midday trading on Wednesday, reaching $22.63. 128,097 shares of the stock traded hands, compared to its average volume of 344,335. The stock has a market capitalization of $620.83 million, a PE ratio of -3.43 and a beta of -0.24. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31. The business has a 50-day moving average of $33.59 and a two-hundred day moving average of $29.94.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. Research analysts anticipate that AnaptysBio will post -6.84 earnings per share for the current year.
In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the firm's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last ninety days. Insiders own 33.70% of the company's stock.
A number of institutional investors have recently modified their holdings of ANAB. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio during the first quarter worth $38,000. Values First Advisors Inc. acquired a new position in AnaptysBio during the third quarter worth about $49,000. nVerses Capital LLC increased its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after buying an additional 1,400 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after acquiring an additional 2,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 2,600 shares in the last quarter.
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.